Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now ...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib.[1] These data, which will be presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Look at Three Decades of Real-World Mesothelioma Statistics
Despite clinical trials that often produce inflated expectations, real-world survival rates for pleural mesothelioma have failed to advance significantly over the past three decades, according to one recent study in Canada. Celebrated treatment advances have fallen short for the average patient diagnosed with this rare cancer caused by exposure to asbestos. “This is a story about a lack of progress. What we’ve seen is kind of underwhelming,” Dr. Paul Wheatley-Price, associate professor of medicine at University of Ottawa and thoracic oncologist at The Ottawa Hospital Cancer Centre, told The Mesothel...
Source: Asbestos and Mesothelioma News - May 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
January 28, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings sho...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Study: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing clinical trial. Median overall survival was more than four months better than the control group receiving chemotherapy alone in the randomized trial. ONCOS-102 is manufactured by Targovax, a small Scandinavian biotech company focused on...
Source: Asbestos and Mesothelioma News - December 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Lung Cancer Trial Could Benefit Mesothelioma Patients
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II clinical research trial is focusing on non-small cell lung cancer and will enroll approximately 66 patients across the U.S. Keytruda, Merck’s anti-PD-1 therapy, works as a checkpoint inhibitor and allows the immune system to identify and attack cancer cells hiding within the PD-1 pathway. The FDA approved Keytruda for mesothelioma as the first immunotherapy treatment for the disease in 2020. Novocure, a global oncology company, has been developing...
Source: Asbestos and Mesothelioma News - August 19, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Immunotherapy Combination Extends Mesothelioma Survival
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination. Patients in the randomized mesothelioma clinical trial who were treated with ipilimumab (Yervoy) and nivolumab (Opdivo) had a median overall survival of 18.1 months, compared to 14.1 months for those receiving chemotherapy. The results of the mesothelioma trial, which was sponsored by Bristol Myers Squibb, were presented at the recent World Conference on Lung Cancer virtual meeting. Authors of the study said it was the first time an immuno...
Source: Asbestos and Mesothelioma News - August 11, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

More Mesothelioma Cancer Centers Using Tumor Treating Fields
Tumor Treating Fields is one of the newest treatments on the market for pleural mesothelioma cancer patients with metastatic disease. The device is also available to patients with locally advanced cancer who are not candidates for mesothelioma surgery. Clinical trials of the treatment, previously known as NovoTTF-100L, extended the survival of mesothelioma patients by more than six months compared to those receiving only chemotherapy. The device is now called Optune Lua and has been available outside of clinical trials for over a year. More physicians and treatment centers are becoming certified to prescribe the treatmen...
Source: Asbestos and Mesothelioma News - July 21, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Keytruda for Certain Mesothelioma Patients
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - June 17, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Durvalumab Phase III Trial Could Change Mesothelioma Care
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cell...
Source: Asbestos and Mesothelioma News - May 28, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Durvalumab added to standard chemotherapy improved overall survival in mesothelioma
(ECOG-ACRIN Cancer Research Group) PrECOG, LLC is reporting on its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma. The trial evaluated adding durvalumab, an immune checkpoint antibody targeting PD-L1, to pemetrexed and cisplatin chemotherapy in 55 patients of any histologic subtype. The study met its primary endpoint with a median overall survival of 20.4 months as compared to the historical control of 12.1 months. The combination was well-tolerated with no unexpected toxicities. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2020 Category: Cancer & Oncology Source Type: news

FDA approves Roche ’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer
Basel, 19 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of tumour cells [TC ≥ 50%] or PD-L1 stained tumour-infiltrating [IC] covering ≥ 10% of the tumour area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumour aberrations.“We are pleased to offer people with certain types of lung cancer a new chemothera...
Source: Roche Media News - May 19, 2020 Category: Pharmaceuticals Source Type: news

Latest Clinical Trial for Pleural Mesothelioma Opens in Georgia
This study is open also to patients with lung cancer or urothelial cancer. In the trial, the use of cabozantinib will be combined with standard-of-care Alimta, the chemotherapy drug generically known as pemetrexed. The study is designed to establish a safe and effective dosage level for both agents when used together. Cabozantinib is known as an inhibitor. It blocks signals that encourage the growth of new blood vessels needed for cancer cells to divide and grow. Blocking those signals can shrink tumors or even cause tumor cell death, leading to significantly longer survival for patients. Cabozantinib will be taken orall...
Source: Asbestos and Mesothelioma News - May 6, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being cond...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Duke Study Challenges Mesothelioma Chemotherapy Practices
Neoadjuvant chemotherapy — often used before aggressive surgery — has shown no definitive survival benefit for patients with pleural mesothelioma cancer, according to a recent study at the Duke University Medical Center. The study strengthened the growing belief among mesothelioma specialists that the combination of chemotherapy drugs cisplatin and pemetrexed might be a more effective treatment after surgery than before. “I think the study provides a little more evidence to support what those of us were seeing, that (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - April 16, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Carboplatin-Pemetrexed Effective for Elderly Patients With Non-small Cell Lung Cancer Carboplatin-Pemetrexed Effective for Elderly Patients With Non-small Cell Lung Cancer
Carboplatin plus pemetrexed followed by maintenance pemetrexed is an effective alternative to docetaxel monotherapy for elderly patients with advanced nonsquamous non-small cell lung cancer (NSCLC), researchers in Japan report.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Phase III Study Shows Combination Treatment to be Effective for NSCLC
This study found that carboplatin-pemetrexed treatment followed by pemetrexed maintenance was a valid option for first-line treatment of elderly patients with advanced nonsquamous non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 16, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA grants priority review to Roche ’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanc ed non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing. The FDA is expected to make a decision on approval by June 19, 2020.“In the IMpower110 study, Tecen...
Source: Roche Investor Update - February 19, 2020 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanc ed non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing. The FDA is expected to make a decision on approval by June 19, 2020.“In the IMpower110 study, Tecen...
Source: Roche Media News - February 19, 2020 Category: Pharmaceuticals Source Type: news

Pemfexy (Pemetrexed Injection for Intravenous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2020 Category: Drugs & Pharmacology Source Type: news

Alternative to Alimta Coming for Mesothelioma Patients
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - February 12, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Pemfexy (Pemetrexed Injection for Intravenous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 12, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Pemfexy (pemetrexed for injection) as a Branded Alternative to Alimta
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE) February 10, 2020 --Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the“Company”) today announced that it has received final approval from the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 10, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Pemetrexed for Injection for Nonsquamous Non-Small Cell Lung Cancer
The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - February 10, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

ONCOS-102 Shows Promise in Combination Mesothelioma Treatment
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - January 27, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Latest Mesothelioma Clinical Trial Opens at Memorial Sloan Kettering
Memorial Sloan Kettering Cancer Center in New York City has opened its latest clinical trial for patients with pleural mesothelioma, studying the effectiveness of an immunotherapy and chemotherapy combination prior to aggressive surgery. The novel feasibility study will determine if the use of Opdivo (nivolumab) with Alimta (pemetrexed) and either cisplatin or carboplatin — without delaying scheduled surgery — can significantly extend patient survival time. The hope is to duplicate earlier effectiveness of that same combination with other cancers. “It has been tried with promising results,” Memorial...
Source: Asbestos and Mesothelioma News - November 27, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Miami Cancer Institute Begins Using Novel Treatment for Mesothelioma
The Miami Cancer Institute on Thursday will begin using the innovative Tumor Treating Fields device for patients with malignant pleural mesothelioma. It is the first new treatment approved for mesothelioma by the U.S. Food and Drug Administration in more than 15 years. “This is actually pretty exciting for us,” Dr. Rupesh Kotecha, the radiation oncologist who will oversee the treatment protocol in Miami, told The Mesothelioma Center at Asbestos.com. “It’s another tool in our armamentarium. It’s something we can offer patients that has shown a real benefit.” The noninvasive Tumor Treating...
Source: Asbestos and Mesothelioma News - November 6, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Pemetrexed + cisplatin in NSCLC not cost effective in Thailand
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2019 Category: Drugs & Pharmacology Source Type: news

Tumor Treating Fields Showing Early Success for Mesothelioma
Dr. Giovanni Ceresoli doesn’t think Tumor Treating Fields will work for every patient with mesothelioma cancer, but he knows it will work for some. They are in his clinic. As the principal investigator of the multicenter clinical trial that led to approval by the U.S. Food and Drug Administration in May, Ceresoli has played a major role in the development of this latest mesothelioma treatment. “It might be too early to say this is a major breakthrough — we need more data — but I hope it is. I know it’s something promising, very promising,” Cerosoli told The Mesothelioma Center at Asbest...
Source: Asbestos and Mesothelioma News - October 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Keytruda for Mesothelioma Flops in Phase III Clinical Trial
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - October 7, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). (Source: Roche Investor Update)
Source: Roche Investor Update - September 27, 2019 Category: Pharmaceuticals Source Type: news

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). (Source: Roche Media News)
Source: Roche Media News - September 27, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT). (Source: Roche Media News)
Source: Roche Media News - September 12, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT). (Source: Roche Investor Update)
Source: Roche Investor Update - September 12, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta
The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta. (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Mesothelioma Study Explores New Treatment When Chemotherapy Fails
A clinical trial is exploring whether a novel immunotherapy/antiangiogenic combination can serve as an effective second-line treatment for pleural mesothelioma. Early indications of the four-center, phase II clinical trial are positive. The combination involves nivolumab (Opdivo) , a well-known immunotherapy drug, and ramucirumab (Cyramza), a therapy drug that blocks the formation of blood vessels needed for new tumor growth. The Food and Drug Administration approved both drugs for the treatment of other cancers, but this clinical trial is the first to test them in combination for mesothelioma. The single-arm trial began i...
Source: Asbestos and Mesothelioma News - August 26, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

What Is the Optimal Maintenance Therapy in Advanced NSCLC?
A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat  non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Once-Promising Drug Ofev Fails in Mesothelioma Clinical Trial
The search for a cure of mesothelioma hit another roadblock recently when a once-promising immunotherapy drug, combined with standard chemotherapy, failed to slow disease progression in a phase III study. The multicenter study covering 27 countries involved Ofev (nintedanib), a small-molecule enzyme inhibitor drug that had shown considerable potential in earlier studies. Lancet Respiratory Medicine published the trial results, signaling another setback for the highly anticipated use of certain immunotherapy drugs to treat mesothelioma. “Making significant improvements in systemic therapy for malignant pleural mesothe...
Source: Asbestos and Mesothelioma News - July 30, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Avastin Improves Quality of Life for Mesothelioma Patients
A research team from France has documented the health-related quality-of-life benefits of adding Avastin (bevacizumab) to chemotherapy for pleural mesothelioma patients, endorsing its addition to standard-of-care treatment. The recent quality-of-life analysis was a secondary endpoint of an earlier, multicenter clinical trial in France that showed an almost three-month median survival improvement when adding Avastin. The latest study demonstrated that adding Avastin to cisplatin and Alimta (pemetrexed) did not negatively impact quality of life — a problem with several other cancers because of the increased toxicity. &...
Source: Asbestos and Mesothelioma News - July 8, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Compound Could Make Chemotherapy More Effective
A research team from the Duke University Medical Center and the Massachusetts Institute of Technology has uncovered a new compound with potential to make chemotherapy more effective in treating various cancers. The small-molecule inhibitor drug — JH-RE-06 — showed an ability to better-sensitize tumors to Cisplatin, the popular chemotherapy drug most often used for mesothelioma cancer patients. When combined with Cisplatin, the drug also showed an ability to prevent those tumor cells from becoming treatment resistant, a common problem with this rare cancer caused by asbestos exposure. The research was done on l...
Source: Asbestos and Mesothelioma News - June 27, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Adding Bevacizumab Improves Overall Survival in NSCLC
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non - small cell lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 18, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Adding Bevacizumab Improves Overall Survival in NSCLC
TUESDAY, June 18, 2019 -- The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 18, 2019 Category: Pharmaceuticals Source Type: news